ProxyMiner / Company
IONIS PHARMACEUTICALS INCIONS
Latest proxy: 2026 · view on SEC ↗ · CIK 0000874015
CEO total pay
$13,350,777
Brett P. Monia · 2025
Say on pay
96%
Latest disclosed shareholder vote
CEO pay ratio
CD&A44 to 1
Median employee: $304,680
Compensation committee
CD&ACompensation Committee
Per the latest proxy
Filings indexed: 2 · 2026 · 2025
Executive pay
What did they pay them?
From the Summary Compensation Table. Pay mix and YoY are computed from these rows.
| Executive | Role | TotalYoY | Pay mix | Salary | Stock | Cash incentive | Other |
|---|---|---|---|---|---|---|---|
Brett P. Monia2025 compensation | Chief Executive Officer | $13,350,777↓ 13% | 88% at-risk | $1,051,776 | $4,297,208 | — | $18,009 |
Elizabeth L. Hougen2025 compensation | EVP, Finance and Chief Financial Officer | $4,422,302↓ 13% | 79% at-risk | $729,750 | $1,544,265 | — | $43,009 |
Richard S. Geary2025 compensation | EVP, Chief Development Officer | $3,331,400↓ 4% | 76% at-risk | $622,074 | $1,095,930 | — | $47,831 |
Brian Birchler2025 compensation | EVP, Corporate and Development Operations | $3,245,054 | 77% at-risk | $580,154 | $1,095,930 | — | $48,009 |
Eric Swayze2025 compensation | EVP, Research | $3,233,339 | 77% at-risk | $589,013 | $1,095,930 | — | $18,009 |
Patrick R. O’Neil2025 compensation | EVP, Chief Legal Officer and General Counsel | $3,210,608↓ 6% | 76% at-risk | $611,791 | $1,095,930 | — | $18,009 |
Pay mix: base cash incentive equity other
CD&A excerpt
Compensation discussion & analysis
Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.
Read the full CD&A on SEC.gov ↗
Peer comparison
Who they benchmark against
Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.
2025 Peer Group
15 members · 2 in ProxyMiner
UAL · United Airlines Holdings, Inc.OIS · OIL STATES INTERNATIONAL, INCDIA · SPDR DOW JONES INDUSTRIAL AVERAGE ETF TRUSTBGHL · BILLION GROUP HOLDINGS LtdAXSM · Axsome Therapeutics, Inc.BCRX · BIOCRYST PHARMACEUTICALS INCCORT · CORCEPT THERAPEUTICS INCTGT · TARGET CORPBMRN · BIOMARIN PHARMACEUTICAL INCINCY · INCYTE CORPJAZZ · Jazz Pharmaceuticals plcNBIX · NEUROCRINE BIOSCIENCES INCUTHR · UNITED THERAPEUTICS CorpALNY · ALNYLAM PHARMACEUTICALS, INC.IRWD · IRONWOOD PHARMACEUTICALS INCPeer Group
6 members · 0 in ProxyMiner
AXSM · Axsome Therapeutics, Inc.BCRX · BIOCRYST PHARMACEUTICALS INCBlueprint Medicines Corp (BPMC)CORT · CORCEPT THERAPEUTICS INCExact Sciences Corp (EXAS)INCY · INCYTE CORPPeer Group
18 members · 0 in ProxyMiner
ACAD · ACADIA PHARMACEUTICALS INCALKS · Alkermes plc.FOLD · AMICUS THERAPEUTICS, INC.APLS · Apellis Pharmaceuticals, Inc.AXSM · Axsome Therapeutics, Inc.BCRX · BIOCRYST PHARMACEUTICALS INCBMRN · BIOMARIN PHARMACEUTICAL INCCORT · CORCEPT THERAPEUTICS INCEXEL · EXELIXIS, INC.HALO · HALOZYME THERAPEUTICS, INC.INCY · INCYTE CORPINSM · INSMED IncJAZZ · Jazz Pharmaceuticals plcNBIX · NEUROCRINE BIOSCIENCES INCPTCT · PTC THERAPEUTICS, INC.SRPT · Sarepta Therapeutics, Inc.RARE · Ultragenyx Pharmaceutical Inc.UTHR · UNITED THERAPEUTICS Corp
Governance
Policy guardrails
hedging
prohibited
“Anti-Hedging Policy and Anti-Pledging Policy We explicitly prohibit employees from “shorting” and hedging against our stock and from pledging our stock”
pledging
prohibited
“In addition, we also prohibit all directors and employees, including our named executive officers, from pledging our stock as collateral”
clawback
present
“Clawback Policy We have a recoupment/“clawback” policy”
stock ownership guidelines
present
“Stock Ownership Guidelines and Holding Periods”
change in control
Severance and Change in Control Arrangements
“Severance and Change in Control Arrangements”
compensation consultant
independent
“independent compensation consultant”
compensation committee
Compensation Committee
“The Compensation Committee”
Performance markers
Metric facts
revenue
$2.7 billion
“evaluation of each key objective and the related achievements for 2025. The Compensation Committee set the Company Performance Factor for the 2025 MBO award at 190% in recognition of a year full of many significant accom…”
time equity mix
—
“inued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the “Current Participants”), the vesting of any …”
say on pay
96%
“votes cast in favor of our “say on pay””
ceo pay ratio
44 to 1
“of the Summary Compensation Table. For 2025, the median annual total compensation of our employees (other than our CEO) was $304,680 and the annual total compensation of our CEO, as reported in the Summary Compensation T…”
median employee compensation
$304,680
“our median employee for 2024 using the following methodology: •We included all employees of Ionis who were employed by us on December 31, 2024. 86 •We identified our median employee from this employee population based on…”
Ask
Anything about IONIS PHARMACEUTICALS INC’s 2026 proxy
Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.
Loading the Ask interface…